Animal models of neurodegenerative diseases

Revista Brasileira de Psiquiatria

Volumn 35, Issue SUPPL.2, 2013, Pages

  Ribeiro, Fabíola Mara ^a   Camargos, Elizabeth Ribeiro da Silva ^a   De Souza, Leonardo Cruz ^a   Teixeira, Antonio Lucio ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Alzheimer's disease; Animal models; Huntington's disease; Neurodegenerative diseases; Parkinson's disease

Indexed keywords

AMYLOID BETA PROTEIN; DOPAMINE; INTERLEUKIN 1BETA; PRESENILIN 1; PRESENILIN 2; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE SEVERITY; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUNTINGTON CHOREA; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHENOTYPE; PREVALENCE; PROTEIN PHOSPHORYLATION;

ALZHEIMER DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; HUNTINGTON DISEASE; PARKINSON DISEASE;

EID: 84888176939     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/1516-4446-2013-1157     Document Type: Article

References (120)

1. Wimo A, Winblad B, Jonsson L. The worldwide societal costs of dementia: Estimates for 2009. Alzheimers Dement. 2010;6:98-103.
2. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet. 2011;377:1019-31.
3. Duyckaerts C, Potier MC, Delatour B. Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol. 2008;115:5-38.
4. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010;362:329-44.
5. LaFerla FM, Green KN. Animal models of Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2. pii:a006320.
6. Blurton-Jones M, Laferla FM. Pathways by which Abeta facilitates tau pathology. Cur Alzheimer Res. 2006;3:437-48.
7. Esch FS, Keim PS, Beattie EC, Blacher RW, Culwell AR, Oltersdorf T, et al. Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science. 1990;248:1122-4.
8. Duyckaerts C, Delatour B, Potier MC. Classification and basic pathology of Alzheimer disease. Acta Neuropathol. 2009;118:5-36.
9. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9:119-28.
10. Hyman BT. Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch Neurol. 2011;68:1062-4.
11. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572-80.
12. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298:789-91.
13. Frautschy SA, Yang F, Calderon L, Cole GM. Rodent models of Alzheimer's disease: rat A beta infusion approaches to amyloid deposits. Neurobiol Aging. 1996;17:311-21.
14. Van Dam D, De Deyn PP. Animal models in the drug discovery pipeline for Alzheimer's disease. Br J Pharmacol. 2011;164:1285-300.
15. Savonenko AV, Xu GM, Price DL, Borchelt DR, Markowska AL. Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APP SWE. Neurobiol Dis. 2003;12:194-211.
16. Kosik KS, Joachim CL, Selkoe DJ. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci U S A. 1986;83:4044-8.
17. Wood JG, Mirra SS, Pollock NJ, Binder LI. Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau). Proc Natl Acad Sci U S A. 1986;83:4040-3.
18. Gotz J, Deters N, Doldissen A, Bokhari L, Ke Y, Wiesner A, et al. A decade of tau transgenic animal models and beyond. Brain Pathol. 2007;17:91-103.
19. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperpho-sphorylated tau aggregates via the proteasome. Neuron. 2004;43:321-32.
20. Tseng BP, Green KN, Chan JL, Blurton-Jones M, LaFerla FM. Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol Aging. 2008;29:1607-18.
21. Keller JN, Hanni KB, Markesbery WR. Impaired proteasome function in Alzheimer's disease. J Neurochem. 2000;75:436-9.
22. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001;293:1487-91.
23. Gotz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science. 2001;293:1491-5.
24. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science. 2007;316:750-4.
25. Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, et al. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron. 2010;68:1067-81.
26. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell. 2010;142:387-97.
27. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci. 2005;8:1051-8.
28. Shen J, Bronson RT, Chen DF, Xia W, Selkoe DJ, Tonegawa S. Skeletal and CNS defects in Presenilin-1-deficient mice. Cell. 1997;89:629-39.
29. Herreman A, Hartmann D, Annaert W, Saftig P, Craessaerts K, Serneels L, et al. Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc Natl Acad Sci U S A. 1999;96:11872-7.
30. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci. 2001;4:231-2.
31. Ohno M, Sametsky EA, Younkin LH, Oakley H, Younkin SG, Citron M, et al. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron. 2004;41:27-33.
32. Wen PH, Shao X, Shao Z, Hof PR, Wisniewski T, Kelley K, et al. Overexpression of wild type but not an FAD mutant presenilin-1 promotes neurogenesis in the hippocampus of adult mice. Neurobiol Dis. 2002;10:8-19.
33. Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 1996;383:710-3.
34. Oyama F, Sawamura N, Kobayashi K, Morishima-Kawashima M, Kuramochi T, Ito M, et al. Mutant presenilin 2 transgenic mouse: effect on an age-dependent increase of amyloid beta-protein 42 in the brain. J Neurochem. 1998;71:313-22.
35. Jankowsky JL, Slunt HH, Gonzales V, Jenkins NA, Copeland NG, Borchelt DR. APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1. Neurobiol Aging. 2004;25:885-92.
36. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409-21.
37. Santana S, Rico EP, Burgos JS. Can zebrafish be used as animal model to study Alzheimer's disease? Am J Neurodegener Dis. 2012;1:32-48.
38. Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, et al. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science. 2001;293:711-4.
39. Jackson GR, Wiedau-Pazos M, Sang TK, Wagle N, Brown CA, Massachi S, et al. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron. 2002;34:509-19.
40. Fossgreen A, Bruckner B, Czech C, Masters CL, Beyreuther K, Paro R. Transgenic Drosophila expressing human amyloid precursor protein show gamma-secretase activity and a blistered-wing phenotype. Proc Natl Acad Sci U S A. 1998;95:13703-8.
41. Iijima K, Liu HP, Chiang AS, Hearn SA, Konsolaki M, Zhong Y. Dissecting the pathological effects of human Abeta40 and Abeta42 in Drosophila: a potential model for Alzheimer's disease. Proc Natl Acad Sci U S A. 2004;101:6623-8.
42. Greeve I, Kretzschmar D, Tschape JA, Beyn A, Brellinger C, Schweizer M, et al. Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila. J Neurosci. 2004;24:3899-906.
43. Sonnhammer EL, Durbin R. Analysis of protein domain families in Caenorhabditis elegans. Genomics. 1997;46:200-16.
44. Link CD. Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci U S A. 1995;92:9368-72.
45. Link CD. C. elegans models of age-associated neurodegenerative diseases: lessons from transgenic worm models of Alzheimer's disease. Exp Gerontol. 2006;41:1007-13.
46. Kraemer BC, Zhang B, Leverenz JB, Thomas JH, Trojanowski JQ, Schellenberg GD. Neurodegeneration and defective neurotrans-mission in a Caenorhabditis elegans model of tauopathy. Proc Natl Acad Sci U S A. 2003;100:9980-5.
47. Miyasaka T, Ding Z, Gengyo-Ando K, Oue M, Yamaguchi H, Mitani S, et al. Progressive neurodegeneration in C. elegans model of tauopathy. Neurobiol Dis. 2005;20:372-83.
48. Willis AL, Evanoff BA, Lian M, Criswell SR, Racette BA. Geographic and ethnic variation in Parkinson disease: a population-based study of US medicare beneficiaries. Neuroepidemiology. 2010;34:143-51.
49. De Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the Europarkinson collaborative study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997;62:10-5.
50. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79:368-76.
51. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet. 2009;373:2055-66.
52. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004;318:121-134.
53. Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordowr JH, Rodriguez M, et al. Missing pieces in the Parkinson's disease puzzle. Nat Med. 2010;16:653-661.
54. Tieu K. A guide to neurotoxic animal models of Parkinson's disease. Cold Spring Harb Perspect Med. 2011;1:a009316.
55. Pearce RK, Owen A, Daniel S, Jenner P, Marsden CD. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J Neural Transm. 1997;104:661-677.
56. Floor E, Wetzel MG. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhy-drazine assay. J Neurochem. 1998;70:268-275.
57. Bezard E, Przedborski S. A tale on animal models of Parkinson's disease. Mov Disord. 2011;26:993-1002.
58. Bezard E, Gross CE, Fournier MC, Dovero S, Bloch B, Jaber M. Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp Neurol. 1999;155:268-273.
59. Hazell AS, Norenberg MD. Manganese decreases glutamate uptake in cultured astrocytes. Neurochem Res. 1997;22:1443-1447.
60. Przedborski S, Tieu K, Perier C, Vila M. MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J Bioenerg Biomembr. 2004;36:375-379.
61. Porras G, Li Q, Bezard E. Modeling Parkinson's disease in primates: the MPTP model. Cold Spring Harb Perspect Med. 2012;2:a009308.
62. Jenner P. From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease. Parkinsonism Relat Disord. 2009;15:S18-23.
63. Purisai MG, McCormack AL, Langston WJ, Johnston LC, Di Monte DA. Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates. Neurobiol Dis. 2005;20:898-906.
64. Barcia C, Ros CM, Annese V, Gómez A, Ros-Bernal F, Aguado-Year D, et al. IFN-c signaling, with the synergistic contribution of TNF-a, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease. Cell Death Dis. 2011;2:e142.
65. Prediger RD, Aguiar AS Jr, Moreira EL, Matheus FC, Castro AA, Walz R, et al. The Intranasal Administration of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP): A New Rodent Model to Test Palliative and Neuroprotective Agents for Parkinson's disease. Curr Pharm Des. 2001;17:489-507.
66. Prediger RD, Aguiar AS Jr, Matheus FC, Walz R, Antoury L, Raisman-Vozari R, et al. Intranasal administration of neurotoxicants in animals: support for the olfactory vector hypothesis of Parkinson's disease. Neurotox Res. 2012;21:90-116.
67. Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, et al. Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci. 2003;23:10756-10764.
68. Mazzio EA, Reams RR, Soliman KF. The role of oxidative stress, impaired glycolysis and mitochondrial respiratory redox failure in the cytotoxic effects of 6-hydroxydopamine in vitro. Brain Res. 2004;1004:29-44.
69. Duty S, Jenner P. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol. 2011;164:1357-1391.
70. Saura J, Parés M, Bové J, Pezzi S, Alberch J, Marin C, et al. Intranigral infusion of interleukin-1beta activates astrocytes and protects from subsequent 6-hydroxydopamine neurotoxicity. J Neurochem. 2003;85:651-661.
71. Mosley RL, Hutter-Saunders JA, Stone DK, Gendelman HE. Inflammation and adaptative immunity in Parkinson's disease. Cold Spring Harb Perspect Med. 2012;2:a009381.
72. Scholz SW, Mhyre T, Ressom H, Shah S, Federoff HJ. Genomics and Bioinformatics of Parkinson's Disease. Cold Spring Harb Perspect Med. 2012;2:a009449.
73. Yue Z, Lachenmayer ML. Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications. Mov Disord. 2011;26:1386-1397.
74. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett. 1994;165:208-210.
75. Scalzo P, Kümmer A, Cardoso F, Teixeira AL. Increased serum levels of soluble tumor necrosis factor-alpha receptor-1 in patients with Parkinson's disease. J Neuroimmunol. 2009;216:122-125.
76. Dutta G, Zhang P, Liu B. The Lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery. Fundam Clin Pharmacol. 2008;22:453-464.
77. Clark IE, Dodson MW, Jiang C, Cao JH, Huth JR, Seol JH, et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature. 2006;441:1162-1166.
78. Sha D, Chin LS, Li L. Phosphorylation of Parkin by Parkinson disease-linked kinase PINK1 activates Parkin E3 ligase function and NF-kB signaling. Hum Mol Genet. 2010;19:352-363.
79. Guo M. Drosophila as a model to study mitochondrial dysfunction in Parkinson's disease. Cold Spring Harb Perspect Med. 2012;2:a009944.
80. Ng CH, Guan MS, Koh C, Ouyang X, Yu F, Tan EK, et al. AMP kinase activation mitigates dopaminergic dysfunction and mitochon-drial abnormalities in Drosophila models of Parkinson's disease. J Neurosci. 2012;32:14311-14317.
81. Li SH, Li XJ. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet. 2004;20:146-154.
82. Young AB. Huntingtin in health and disease. J Clin Invest. 2003;111:299-302.
83. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell. 1993;72:971-983.
84. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004;431:805-810.
85. Sanchez I, Mahlke C, Yuan J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature. 2003;421:373-379.
86. Myers RH, Vonsattel JP, Stevens TJ, Cupples LA, Richardson EP, Martin JB, et al. Clinical and neuropathologic assessment of severity in Huntington's disease. Neurology. 1988;38:341-347.
87. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 1997;90:537-548.
88. Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA, et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet. 1999;8:397-407.
89. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996;87:493-506.
90. Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet. 2003;12: 1555-1567.
91. Gray M, Shirasaki DI, Cepeda C, Andre VM, Wilburn B, Lu XH, et al. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci. 2008;28:6182-6195.
92. Wheeler VC, White JK, Gutekunst CA, Vrbanac V, Weaver M, Li XJ, et al. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum Mol Genet. 2000;9:503-513.
93. Lin CH, Tallaksen-Greene S, Chien WM, Cearley JA, Jackson WS, Crouse AB, et al. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum Mol Genet. 2001;10: 137-144.
94. Menalled LB, Sison JD, Wu Y, Olivieri M, Li XJ, Li H, et al. Early motor dysfunction and striosomal distribution of huntingtin micro-aggregates in Huntington's disease knock-in mice. J Neurosci. 2002;22:8266-8276.
95. Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, Bates GP, et al. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci. 1999;19:3248-57.
96. Lione LA, Carter RJ, Hunt MJ, Bates GP, Morton AJ, Dunnett SB. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J Neurosci. 1999;19:10428-10437.
97. Li H, Li SH, Cheng AL, Mangiarini L, Bates GP, Li XJ. Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. Hum Mol Genet. 1999;8:1227-1236.
98. Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK, et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci. 2000;20:4389-4397.
99. Ona VO, Li M, Vonsattel JP, Andrews LJ, Khan SQ, Chung WM, et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature. 1999;399:263-267.
100. Menalled LB, Chesselet MF. Mouse models of Huntington's disease. Trends Pharmacol Sci. 2002;23:32-39.
101. Menalled L, El-Khodor BF, Patry M, Suarez-Farinas M, Orenstein SJ, Zahasky B, et al. Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol Dis. 2009;35:319-336.
102. Woodman B, Butler R, Landles C, Lupton MK, Tse J, Hockly E, et al. The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Res Bull. 2007;72:83-97.
103. Slow EJ, Graham RK, Osmand AP, Devon RS, Lu G, Deng Y, et al. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc Natl Acad Sci U S A. 2005;102:11402-11407.
104. Wang CE, Tydlacka S, Orr AL, Yang SH, Graham RK, Hayden MR, et al. Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease. Hum Mol Genet. 2008;17:2738-2751.
105. Yuan J, Yankner BA. Apoptosis in the nervous system. Nature. 2000;407:802-809.
106. Mattson MP. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol. 2000;1:120-129.
107. Li XJ, Li S. Influence of species differences on the neuropathology of transgenic Huntington's disease animal models. J Genet Genomics. 2012;39:239-245.
108. Li Z, Karlovich CA, Fish MP, Scott MP, Myers RM. A putative Drosophila homolog of the Huntington's disease gene. Hum Mol Genet. 1999;8:1807-1815.
109. Jackson GR, Salecker I, Dong X, Yao X, Arnheim N, Faber PW, et al. Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. Neuron. 1998;21:633-642.
110. Marsh JL, Walker H, Theisen H, Zhu YZ, Fielder T, Purcell J, et al. Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila. Hum Mol Genet. 2000;9:13-25.
111. Kahsai L, Zars T. Learning and memory in Drosophila: behavior, genetics, and neural systems. Int Rev Neurobiol. 2011;99:139-167.
112. Agrawal N, Pallos J, Slepko N, Apostol BL, Bodai L, Chang LW, et al. Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila. Proc Natl Acad Sci U S A. 2005;102:3777-37781.
113. Satyal SH, Schmidt E, Kitagawa K, Sondheimer N, Lindquist S, Kramer JM, et al. Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans. Proc Natl Acad Sci U S A. 2000;97:5750-5755.
114. Morley JF, Brignull HR, Weyers JJ, Morimoto RI. The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc Natl Acad Sci U S A. 2002;99:10417-10422.
115. Faber PW, Alter JR, MacDonald ME, Hart AC. Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron. Proc Natl Acad Sci U S A. 1999;96:179-184.
116. Parker JA, Connolly JB, Wellington C, Hayden M, Dausset J, Neri C. Expanded polyglutamines in Caenorhabditis elegans cause axonal abnormalities and severe dysfunction of PLM mechanosen-sory neurons without cell death. Proc Natl Acad Sci U S A. 2001;98:13318-13323.
117. Hsu AL, Murphy CT, Kenyon C. Regulation of aging and age-related disease by DAF-16 and heat-shock factor. Science. 2003;300:1142-1145.
118. Faber PW, Voisine C, King DC, Bates EA, Hart AC. Glutamine/ proline-rich PQE-1 proteins protect Caenorhabditis elegans neurons from huntingtin polyglutamine neurotoxicity. Proc Natl Acad Sci U S A. 2002;99:17131-17136.
119. Haldimann P, Muriset M, Vigh L, Goloubinoff P. The novel hydroxylamine derivative NG-094 suppresses polyglutamine protein toxicity in Caenorhabditis elegans. J Biol Chem. 2011;286:18784-18794.
120. Voisine C, Varma H, Walker N, Bates EA, Stockwell BR, Hart AC. Identification of potential therapeutic drugs for huntington's disease using Caenorhabditis elegans. PloS One. 2007;2:e504.